Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

SPTXBullishCorporate Developmentsnews

High materiality8/10

Seaport Therapeutics Prices IPO to Raise $254.9 Million for Drug Development

Apr 30, 2026, 9:57 PM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The strong subscription and anticipated trading debut typically lead to upward market momentum for newly public companies. Historical IPOs in biotech often see significant appreciation in initial trade due to heightened interest and scarcity.

AI summary

What happened, with direct paths to the underlying reporting

Seaport Therapeutics has priced its IPO at $18 per share, aiming to raise $254.9 million to further its neuropsychiatric drug development. With shares starting to trade on May 1, 2026, this funding is pivotal for advancing their innovative therapies targeting mental health disorders.

Seaport Therapeutics priced IPO at $18 per share, raising $254.9 million.
Initial public offering includes 14.16 million shares, with a 30-day option for more.
Shares set to trade on Nasdaq from May 1, 2026.
Offering proceeds critical for neuropsychiatric drug development.
Goldman Sachs, J.P. Morgan managing the offering.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Seaport Therapeutics Prices IPO to Raise $254.9 Million for Drug Development

Seaport Therapeutics Seeks $912 Million Valuation in Upcoming IPO